Advancing treatments for Neurological Disorders

With the innovative use of Alpha 1 Anti-trypsin, Ageronix stands at the forefront of Neurodegenerative Disease research.

A promising breakthrough in the development of new treatments for Neurological Disorders

Read our latest press release here

  • FDA-Recognized
  • Experienced Research Team
  • Commitment to CMT Patients
  • Pioneering AAT Therapies
  • Leading the search for a cure

Three generations of AAT-therapy:

In recognition of our commitment, Ageronix was granted the Orphan Drug Designation (ODD) and the Rare Pediatric Disease (RPD) Designation by the FDA

  • PRE-CLINICAL DEVELOPMENT
    - 2023
  • FDA AWARDS ODD
    July, 2023
  • FDA AWARDS RPD
    AUGUST, 2023
  • CLINICAL TRIALS
    2024 -

For more information please get in touch at:
info@ageronix.com or
+41 223 79 46 43

64, Avenue de la Roseraie 1205, Geneva - Switzerland